Vertex Pharmaceuticals Stock Analysis
VRTX Stock | USD 516.74 14.29 2.84% |
Vertex Pharmaceuticals is overvalued with Real Value of 433.0 and Target Price of 388.67. The main objective of Vertex Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Vertex Pharmaceuticals is worth, separate from its market price. There are two main types of Vertex Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Vertex Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Vertex Pharmaceuticals is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Vertex Stock trading window is adjusted to America/New York timezone.
Vertex |
Vertex Stock Analysis Notes
About 95.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.26. Vertex Pharmaceuticals recorded a loss per share of 1.88. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people. For more information please call MD FASN at 617 341 6100 or visit https://www.vrtx.com.Vertex Pharmaceuticals Quarterly Total Revenue |
|
Vertex Pharmaceuticals Investment Alerts
Vertex Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
Over 95.0% of the company outstanding shares are owned by institutional investors | |
Latest headline from finance.yahoo.com: Lumen Technologies, Inc. Taps Google Cloud AI, Enhances Network Efficiency with Lumen Digital Twin |
Vertex Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Vertex Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
5th of February 2024 Upcoming Quarterly Report | View | |
6th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
5th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Vertex Largest EPS Surprises
Earnings surprises can significantly impact Vertex Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2013-01-29 | 2012-12-31 | -0.08 | -0.09 | -0.01 | 12 | ||
2016-10-25 | 2016-09-30 | 0.18 | 0.16 | -0.02 | 11 | ||
2000-02-16 | 1999-12-31 | 0.01 | 0.03 | 0.02 | 200 |
Vertex Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Vertex Pharmaceuticals' ESG score is a quantitative measure that evaluates Vertex Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Vertex Pharmaceuticals' operations that may have significant financial implications and affect Vertex Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Vertex Pharmaceuticals Thematic Classifications
In addition to having Vertex Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
Vertex Stock Institutional Investors
Shares | Wellington Management Company Llp | 2024-06-30 | 4.1 M | Amundi | 2024-06-30 | 3.5 M | Norges Bank | 2024-06-30 | 3.4 M | Loomis, Sayles & Company Lp | 2024-06-30 | 3.1 M | Massachusetts Financial Services Company | 2024-06-30 | 2.7 M | Ubs Asset Mgmt Americas Inc | 2024-06-30 | 2.6 M | Bank Of America Corp | 2024-06-30 | 2.6 M | Northern Trust Corp | 2024-06-30 | 2.5 M | Legal & General Group Plc | 2024-06-30 | 2.4 M | Capital World Investors | 2024-06-30 | 26.7 M | Vanguard Group Inc | 2024-06-30 | 23 M |
Vertex Market Capitalization
The company currently falls under 'Mega-Cap' category with a current market capitalization of 128.85 B.Vertex Profitablity
The company has Profit Margin (PM) of (0.05) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.41 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.41.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.17 | 0.18 | |
Return On Capital Employed | 0.20 | 0.21 | |
Return On Assets | 0.16 | 0.17 | |
Return On Equity | 0.21 | 0.22 |
Management Efficiency
Vertex Pharmaceuticals has return on total asset (ROA) of 0.1262 % which means that it generated a profit of $0.1262 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0298) %, meaning that it created substantial loss on money invested by shareholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.18 in 2024. Return On Capital Employed is likely to rise to 0.21 in 2024. At this time, Vertex Pharmaceuticals' Return On Assets are fairly stable compared to the past year.Last Reported | Projected for Next Year | ||
Book Value Per Share | 68.22 | 71.63 | |
Tangible Book Value Per Share | 60.74 | 63.78 | |
Enterprise Value Over EBITDA | 24.24 | 23.03 | |
Price Book Value Ratio | 5.96 | 7.46 | |
Enterprise Value Multiple | 24.24 | 23.03 | |
Price Fair Value | 5.96 | 7.46 | |
Enterprise Value | 15.8 B | 8.3 B |
Understanding the operational decisions made by Vertex Pharmaceuticals management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Operating Margin 0.4082 | Profit Margin (0.05) | Beta 0.402 | Return On Assets 0.1262 | Return On Equity (0.03) |
Technical Drivers
As of the 8th of November, Vertex Pharmaceuticals has the Semi Deviation of 1.42, coefficient of variation of 1172.55, and Risk Adjusted Performance of 0.0714. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vertex Pharmaceuticals, as well as the relationship between them.Vertex Pharmaceuticals Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Vertex Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Vertex Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Vertex Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vertex Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vertex Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vertex Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bozic Carmen over two months ago Disposition of 2812 shares by Bozic Carmen of Vertex Pharmaceuticals at 420.58 subject to Rule 16b-3 | ||
Charles Wagner over six months ago Sale by Charles Wagner of 3000 shares of Vertex Pharmaceuticals | ||
Charles Wagner over a year ago Payment of 2707 shares by Charles Wagner of Vertex Pharmaceuticals subject to Rule 16b-3 |
Vertex Pharmaceuticals Outstanding Bonds
Vertex Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vertex Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vertex bonds can be classified according to their maturity, which is the date when Vertex Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
VERTICAL HOLDCO GMBH Corp BondUS92537VAA89 | View | |
VERTICAL U S Corp BondUS92537RAA77 | View | |
US92535UAB08 Corp BondUS92535UAB08 | View |
Vertex Pharmaceuticals Predictive Daily Indicators
Vertex Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vertex Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 33511.06 | |||
Daily Balance Of Power | 0.9565 | |||
Rate Of Daily Change | 1.03 | |||
Day Median Price | 512.41 | |||
Day Typical Price | 513.85 | |||
Price Action Indicator | 11.48 | |||
Period Momentum Indicator | 14.29 | |||
Relative Strength Index | 49.73 |
Vertex Pharmaceuticals Corporate Filings
10Q | 5th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 17th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 3rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 4th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 16th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 12th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 8th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Vertex Pharmaceuticals Forecast Models
Vertex Pharmaceuticals' time-series forecasting models are one of many Vertex Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vertex Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Vertex Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Vertex Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vertex shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vertex Pharmaceuticals. By using and applying Vertex Stock analysis, traders can create a robust methodology for identifying Vertex entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.45 | 0.47 | |
Operating Profit Margin | 0.38 | 0.40 | |
Net Profit Margin | 0.37 | 0.39 | |
Gross Profit Margin | 0.87 | 1.09 |
Current Vertex Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vertex analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vertex analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
388.67 | Buy | 35 | Odds |
Most Vertex analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Vertex stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Vertex Pharmaceuticals, talking to its executives and customers, or listening to Vertex conference calls.
Vertex Stock Analysis Indicators
Vertex Pharmaceuticals stock analysis indicators help investors evaluate how Vertex Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vertex Pharmaceuticals shares will generate the highest return on investment. By understating and applying Vertex Pharmaceuticals stock analysis, traders can identify Vertex Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 10.5 B | |
Common Stock Shares Outstanding | 260.5 M | |
Total Stockholder Equity | 17.6 B | |
Tax Provision | 760.2 M | |
Quarterly Earnings Growth Y O Y | 0.01 | |
Property Plant And Equipment Net | 1.5 B | |
Cash And Short Term Investments | 11.2 B | |
Cash | 10.4 B | |
Accounts Payable | 364.9 M | |
Net Debt | -9.6 B | |
50 Day M A | 474.4154 | |
Total Current Liabilities | 3.5 B | |
Other Operating Expenses | 6.1 B | |
Non Current Assets Total | 8.6 B | |
Forward Price Earnings | 26.5957 | |
Non Currrent Assets Other | 796.7 M | |
Stock Based Compensation | 581.2 M |
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.